Linkedin
RLS logo_header
Linkedin

Biocytogen Announces Adcendo ApS Exercises Antibody Option to Accelerate ADC Development

“We are excited to deploy Biocytogen’s cutting-edge platforms for antibody discovery to support Adcendo’s innovative ADC drug development initiatives,” said Yuelei Shen, Ph.D., president and CEO of Biocytogen. “Our unique RenMice® platform enables the discovery of fully human antibodies with high affinity, low immunogenicity, and favorable developability. With Adcendo’s extensive expertise in ADCs, we are confident that this collaboration will drive the rapid advancement of novel therapies to benefit patients worldwide.”

Read the full story on "Biocytogen Announces Adcendo ApS Exercises Antibody Option to Accelerate ADC Development"

Share:

More News

FDA clears IND application for ORM-1153 for Ph 1 study in patients with R/R AML and other hematologic malignancies

“FDA clearance of the IND for ORM-1153 is an important milestone for Orum, bringing another first-in-class DAC into the clinic and extending our approach into CD123-expressing hematologic malignancies,” said Olaf Christensen, M.D., Chief Medical Officer of Orum Therapeutics. “By combining cell-selective delivery with targeted protein degradation in a single molecule,

IDEAYA Biosciences Announces Clinical Collaboration with Genentech in MTAP-Deleted KRAS G12D-Mutant Pancreatic Cancer

“We are excited to expand our clinical collaboration with Roche to evaluate a second KRAS combination with potential best-in-class MTA-cooperative PRMT5 inhibitor IDE892 for pancreatic cancer patients, where there remains a high unmet medical need. IDEAYA is advancing multiple rational combination strategies for the IDE892 program, including with MAT2A inhibitor

IDMC recommends to continue patient enrolment in Ph 1 ZIMA-101 trial in solid tumor patients

“These encouraging initial safety observations represent an important first step in the clinical evaluation of ZI-MA4-1 and our TCR-NK platform” said Namir Hassan, Chief Executive Officer of Zelluna. “The first patient received all three planned doses, and the independent committee’s recommendation enables us to continue recruitment at the first dose

FDA Fast Track Designation Granted to ERAS-0015 in Patients with Metastatic Pancreatic Adenocarcinoma

“Receiving FTD is an important milestone for ERAS-0015 and reflects the urgent need for new therapies for patients with metastatic pancreatic cancer,” said Jonathan E. Lim, M.D., Erasca’s chairman, CEO, and co-founder. “Together with the encouraging clinical activity and favorable tolerability observed to date, this FTD helps to position us